The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front‐line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125
Open accessAbstract
BACKGROUND: The primary objective of this study was to determine the safety and maximum tolerated dose (MTD) of the antimesothelin immunotoxin SS1(dsFv)PE38 (SS1P) (a recombinant antimesothelin immunotoxin consisting of a murine antimesothelin variable antibody fragment [Fv] linked to PE38, a truncated portion of Pseudomonas exotoxin A) in combination with pemetrexed and cisplatin in chemotherapy‐naive patients with advanced malignant pleural mesothelioma (MPM). Secondary objectives included tumor response, SS1P pharmacokinetics, and serum biomarkers of response. METHODS: Chemotherapy‐naive patients with stage III or IV, unresectable, epithelial or biphasic MPM and normal organ functions were eligible. Pemetrexed (500 mg/m 2 on day 1) and cisplatin (75 mg/m 2 on day 1) were administered every 3 weeks for up to 6 cycles with escalating doses of SS1P administered intravenously on days 1, 3, and 5 during cycles 1 and 2. Tumor response was evaluated every 6 weeks. RESULTS: Twenty‐four patients received SS1P at 4 dose levels from 25 to 55 mcg/kg. Grade 3 fatigue was dose‐limiting in 1 patient at 55 mcg/kg. The MTD of SS1P was established as 45 mcg/kg. Other grade 3 toxicities associated with SS1P included hypoalbuminemia (21%), back pain (13%), and hypotension (8%). Of 20 evaluable patients, 12 (60%) had a partial response, 3 had stable disease, and 5 had progressive disease. Of 13 patients who received the MTD, 10 (77%) had a partial response, 1 had stable disease, and 2 had progressive disease. Objective radiologic responses were associated with significant decreases in serum mesothelin (P=.0030), megakaryocyte potentiating factor (P=.0005), and cancer antigen 125 (P < .0001). CONCLUSIONS: SS1P given with pemetrexed and cisplatin is safe and well tolerated and exhibits significant antitumor activity in patients with unresectable, advanced pleural mesothelioma. Serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125 levels correlated with objective tumor responses. Cancer 2014;120:3311–3319. Published 2014. This article is a U.S. Government work and is in the public domain in the USA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.136 · Cited by 3,060
Cited by
Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors
Morello, A., Sadelain, M., & Adusumilli, P. S. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0583 · Cited by 477
Novel Insights into Mesothelioma Biology and Implications for Therapy
Yap, T. A., Aerts, J. G., Popat, S., & Fennell, D. A. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.42 · Cited by 324
Mesothelin Immunotherapy for Cancer: Ready for Prime Time?
Hassan, R., Thomas, A., Alewine, C., Le, D. T., Jaffee, E. M., & Pastan, I. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.3672 · Cited by 325
Self-citationMalignant pleural mesothelioma: an update on investigation, diagnosis and treatment
Bibby, A. C., Tsim, S., Kanellakis, N., Ball, H., Talbot, D. C., Blyth, K. G., Maskell, N. A., & Psallidas, I. (2016) · European Respiratory Review · doi:10.1183/16000617.0063-2016 · Cited by 316
Clinical Significance of Histologic Subtyping of Malignant Pleural Mesothelioma
Brcic, L., & Kern, I. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.03.38 · Cited by 77
Metadata
- Authors
- Hassan, R., Sharon, E., Thomas, A., Zhang, J., Ling, A., Miettinen, M., Kreitman, R. J., Steinberg, S. M., Hollevoet, K., & Pastan, I.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2014-07-02
- Volume
- 120
- Issue
- 21
- Pages
- 3311-3319
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1503438909
- Cited by
- 168
- References
- 1
- FWCI
- 16.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front‐line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. https://app.cochat.ai/papers/10.1002/cncr.28875
- The paper
- Hassan, R., Sharon, E., Thomas, A., Zhang, J., Ling, A., Miettinen, M., Kreitman, R. J., Steinberg, S. M., Hollevoet, K., & Pastan, I. (2014). Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front‐line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. Cancer. https://doi.org/10.1002/cncr.28875
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.